Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
33.61
+0.24 (0.72%)
May 29, 2026, 4:00 PM EDT - Market closed
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Collegium Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $54.33. The average 1-year stock price forecast is 61.65% higher than the current stock price, while the lowest is $45 (+33.89%) and the highest is $60 (+78.52%).
Price Target: $54.33 (+61.65%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Collegium Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Financial | Truist Financial | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 15, 2026 |
| Barclays | Barclays | Buy Reiterates $56 | Buy | Reiterates | $56 | +66.62% | May 13, 2026 |
| Needham | Needham | Buy Maintains $56 | Buy | Maintains | $56 | +66.62% | May 12, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $60 | Buy | Reiterates | $60 | +78.52% | May 8, 2026 |
| Piper Sandler | Piper Sandler | Hold Maintains $44 | Hold | Maintains | $44 | +30.91% | Apr 23, 2026 |
Financial Forecast
Revenue This Year
889.97M
from 780.57M
Increased by 14.02%
Revenue Next Year
919.86M
from 889.97M
Increased by 3.36%
EPS This Year
7.83
from 1.73
Increased by 351.52%
EPS Next Year
7.77
from 7.83
Decreased by -0.75%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 926.8M | 1.0B | |||||
| Avg | 890.0M | 919.9M | |||||
| Low | 844.1M | 740.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 18.7% | 17.3% | |||||
| Avg | 14.0% | 3.4% | |||||
| Low | 8.1% | -16.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 8.66 | 9.74 | |||
| Avg | 7.83 | 7.77 | |||
| Low | 7.03 | 5.55 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 399.3% | 24.4% | |||
| Avg | 351.5% | -0.8% | |||
| Low | 305.0% | -29.2% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.